Dr. John Cush RheumNow
7 years 4 months ago
Research by Robinson and colleagues at Stanford show that mast cell inhibition or depletion significantly improved osteoarthritis in a mouse model. Mast cell driven tryptase increases inflammation, chondrocyte apoptosis, and cartilage breakdown https://t.co/LpgZUhDHvQ
Dr. John Cush RheumNow
7 years 4 months ago
Dr. Madelaine Feldman's outstanding lecture on Drug Costs in America: The Bad, the Worse and The Despicable, is available for free at RheumNow Live On Demand at https://t.co/1jGiIQXvua. Check it out - you'll be glad you did. #rheumed #rheum https://t.co/MuNzooK8YB
A study of biologic-naïve patients with ankylosing spondylitis (AS) who started therapy with a tumour necrosis factor inhibitor (TNFi) shows that after 5 years only 46% are still on a TNFi and that some are able to lower the dose over time.
A nationwide Swedish Rheumatology register followed 2590 Bio-naïve AS who started a TNFi between 2006–2015.
Dr. John Cush RheumNow
7 years 4 months ago
FDA has approved the worlds most expensive drug - $2.1 million - Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy for spinal muscular atrophy (SMA) that affects 1 in 11,000 newborns https://t.co/hHuymQ3sjV
Dr. John Cush RheumNow
7 years 4 months ago
Metanalysis suggests leflunomide in psoriatic disease is better at treating arthritis (PsA PsARC 77%) than skin disease (psoriasis PASI50 48% & PASI75 25%). Adverse events in 38% and 15% drop out rate. https://t.co/BIPNtYE6Tr
Dr. John Cush RheumNow
7 years 4 months ago
Harvinder S. Luthra, MBBS, Presented with the Albert Nelson Marquis Lifetime Achievement Award by Marquis Who's Who https://t.co/1aTy1axjXL
Dr. John Cush RheumNow
7 years 4 months ago
Large UK study shows central adiposity (waist circumference) signify increases risk of psoriasis and rheumatoid arthritis; not PsA. a cross-sectional study of the UK Biobank https://t.co/eKDpUodSR1
Upadacitinib (UPA) is an oral, selective JAK1-selective inhibitor being developed for use in rheumatoid arthritis patients; Lancet has reported the SELECT-MONOTHERAPY trial showing that UPA is safe and effective in RA patients with an inadequate response to methotrexate (MTX).
This multicenter study randomized 648 patients, of whom 598 (92%) completed week 14.
At week 14, an ACR20 responses were:
The risk of serious infectious events (SIE) with rituximab (RTX) is similar to that seen in other biologics (e.g., RA: 2% or 4.3/100PY), but with prolonged use the risk may change. Recent research says that low IgG levels, RTX induced neutropenia, prior SIE and comorbidities can significantly augment this risk.
A retrospective longitudinal single center study of 700 rheumatic and musculoskeletal diseases (RMDs) treated monitored serum
Dr. John Cush RheumNow
7 years 4 months ago
Lyrica is FDA approved for FM, Neuopathy & adjunctive Rx for partial-onset seizures; but recently failed to meet primary endpoint in a phase III RCT to prevent primary gen tonic-clonic seizures.- but is continuing to develop it for pediatric epilepsy. https://t.co/T9T0Kv1wkP
Dr. John Cush RheumNow
7 years 4 months ago
Prospective study of 4796 pts in Osteoarthritis Initiative shows metformin use in obese pts (BMI >30) was Assoc with significantly less medial cartilage loss (0.71% vs. 1.57%/yr) & a trend towards fewer knee replacements over 6 yrs (OR 0.30, p = 0.11) https://t.co/LD0jFWtSLM
Nearly half of all available vacation days go unused and over 40% of Americans failed to use any vacation days in 2015. Common sense says that taking more time off (not less) is likely to lead to increased work productivity. Your next vacation is essential to building a better you. Here are some tips to insure you get the most from your time off.
Dr. Jack Cush Reviews the news and journal articles from the past week on RheumNow.com
